EFTA00811360.pdf

bgC3 Trip Report: Tel Aviv (August 20-22, 2017) Key takeaways • Advances in immunology and hyperbarics may hold promise in the diagnosis and management of chronic and degenerative disease. • Focused sources of physical energy can be complementary tools in the detection and treatment of disease. • Cognitive decline may best be understood in the context of natural aging and many approaches to brain health are being targeted — and individualized — across the full life span. • Israel's unique geopolitical landscape provides start-up founders cross-disciplinary experiences, including the IDF, to build new technologies and approaches. Background Last week, Drs. Gilla Kaplan (BMGF), Niranjan Bose and traveled to Tel Aviv to • Learn more about the life sciences technology landscape in Israel • Identify life science and other technologies or emerging practices with potential for scale and/or widespread adoption • Validate the most promising of these technologies or practices, especially those with neuroscience application Israel has a strong tradition of putting science and technology at the forefront of its economic development. The country invests 4%-5% of its GDP on R&D each year, which is the highest rate in the world, and has developed leadership in terms of scientists, engineers and patents per capita. Despite its small size, Israel has become an important center for innovation and has a proven track record in fields such as computer science, navigation, nanotechnology, and brain research. Recommendations • There are a few groups pursuing extremely interesting approaches towards AD and neurodegeneration • Foundation and bgC3 should continue to watch the landscape of companies and technologies emerging out of Israel and find a way to stay engaged • There might be great value in planning a 1 day visit for Bill when he is in the region or curating a set of learning/science sessions in Europe with some of the Israeli companies EFTA00811360 Academic Highlights Immune Gatekeeping in Aging and Degenerative Disease Dr. Michael Schwartz Lab: http://www.weizmann.ac.il/neurobiologv/labs/schwartz/ Can immunotherapy treat neurodegeneration? Dr. Schwartz has a notable research background and in the last decade has refocused her lab around harnessing the immune system to combat Alzheimer's disease and age-related dementia — specifically in the potential use of immune checkpoint blockade. Milestones in her studies that have led to this conclusion include: 1. Circulating immune cells support brain plasticity and repair 2. The brain's choroid plexus epithelium —a permissive gateway to the brain 3. Under brain pathologies the gateway (communication) is malfunctioning 4. Immune checkpoint blockade for fighting against Alzheimer's disease These findings (and more) have led to the conclusion that reversing the age-related signature of the aging choroid plexus restores brain function and microglial function. Her current "neuro- immunotherapeutic" direction includes the development of anti-PD-L1 as the first generation of immunotherapy to combat Alzheimer's disease, and searching for novel CNS specific checkpoint targets as the second generation of immunotherapy. They are specifically going after discovering novel antibodies in partnership with Lundbeck. Cellular Rejuvenation Therapy and Biomarker Development Dr. Shai Efrati Lab: http://www.assafh.org/sites/en/clinic/Hifrbaric/Pages/default.aspx Hyperbaric medicine was originally conceptualized to ameliorate the effects of air embolism in deep water divers. Dr. Efrati is proposing new indications for this technology, based on the premise that an immediate and sustained healing response — for all tissues — is stimulated during the temporal delta when dropping oxygen concentration from 100% to ambient levels under high pressure. This reduction in oxygen concentration (rather than an absolute) promotes the production of a number of measurable factors associated with wound healing and cellular rejuvenation. He now seeks to classify and validate the biomarkers he has identified in order to scale the concept and expand the indications for HBOT (hyperbaric oxygen therapy). Dr. Efrati and his lab partners at Tel Aviv University have proven that HBOT can induce neuroplasticity in stroke and traumatic brain injuries even years after an acute incident, and also reverse early cognitive decline. However since he is the only lab in the world applying the technology in this way, he has struggled to gain the momentum required to take this concept to greater scale. Despite this, he continues to treat hundreds of patients per day and has a waiting list of more than 10,000 people. EFTA00811361 Companies MyndYou Concept Voice recognition of cognitive decline Stage R&D; raised $320K till date Contact http://www.myndyou.com/ Ruth Baruchi, Founder and CEO (ruthtaimvndvou.com) Notes MyndYou is developing a mobile platform for monitoring patients with cognitive decline, based on participation, speech and language patterns. The platform collects and analyzes passive cognitive and behavioral data in order to generate actionable insights for therapists — with algorithms informed by longitudinal (youtube) videos of public figures with known cognitive decline. SipNose Concept Nasal drug delivery device Stage Clinical Trial Contact https://www.sipnose.com/ Iris Schichor, Founder and CEO ([email protected]) Notes SipNose (nasal drug delivery device): SipNose focuses on nose-to-brain medical applications and is developing a nasal delivery platform for local, systemic, and central nervous system indications that bypasses the blood-brain barrier. SipNose's intranasal drug delivery platform uses a mechanism that can improve efficacy, patient compliance, and safety. SipNose's noninvasive devices ensure accurate dose delivery via the nasal cavity and incorporate a simple, efficient mechanism to allow localization of the aerosolized drug in the olfactory epithelium, resulting in better absorption to the olfactory bulb and brain. Currently under investigation using midazolam, cannabis, and topiramate but fit for chemo, protein drugs and biologicals. The founder is a former post-doc in Dr. Langer's laboratory. ContinUse Concept Nanoscale resolution contactless biometrics Stage R&D. Founded in Q12015 and have raised $7.2 million in equity. The product will likely enter commercial markets through a partnership with Motorola with a price point of $30 additional per device at scale. Engaged in a technical partnership with GE as well. Contact https://www.cu-bx.com/ Asher Polani, co-founder and CEO ([email protected]) Notes ContinUse has developed a remote, contactless biometrics based on mechanical oscillations — basically a remote optical stethoscope. The company's sensor performs active and continuous biometrics, scanning a distance of up to several hundred meters. The sensor is based on nanotechnology that detects molecular vibration and is unaffected by clothing or other physical conditions. ContinUse currently measures over 20 bioparameters at nanoscale resolution (heart rate, respiration rate, blood pressure, glucose levels, alcohol levels, etc.) — albeit indirectly. There is an appetite to develop beyond — into coagulation or pathologic states. EFTA00811362 Breezometer Concept I Real time hyperlocal air quality management platform Stage Released. Company has raised $5 million to date. Contact https://breezometer.com/ Ran Korber, co-founder and CEO (rank([email protected]) Notes BreezoMeter utilizes big-data infrastructure to continuously gather air quality and weather measurements from thousands of sources (e.g., satellites, weather, traffic, and monitoring stations). They do not deploy any of their own sensors. The collected data is processed through algorithms to provide air quality information with hyperlocal street- level accuracy in more than 24,000 cities. BreezoMeter also provides personalized health solutions for adults and children, athletes, and people with health sensitivities. Propellor health (US based health focused company) is powered by Breezometer data. Somatix Concept Hand gesture-based behavioral analytic platform Stage Beta Contact http://somatix.com/ Eran Ofer, co-founder and CEO erar .natix.com) Notes Somatix develops data-integrated behavioral health therapies. The company's technology utilizes sensors in smartwatches and wristbands to enable real-time measurement of smoking, drinking, eating, and other hand-to-mouth gestures (tremor, bradykinesia, medication compliance). The data can then be mined for interpretations and applications for both individual and healthcare enterprise clients. Intendu Concept Adaptive gaming platform for cognitive training Stage Beta Contact http://www.intendu.com Nimrod Madar, founder and CEO ([email protected]) Notes The Intendu solution is based on body-controlled, adaptive videogames. The games include interaction with characters and using natural body gestures within functional environments. The Intendu training platform provides real-time personalization through games targeting cognitive function. The platform has been tested in populations with cognitive impairments due to various brain conditions including cognitive decline. More Intendu Functional Brain Trainer - Intro Video ElMinda Concept EEG-based high resolution functional map of the brain Stage Released Contact http://www.elminda.com Ronen Gadot, CEO and founder ([email protected]) Notes ElMindA's BNA technology is based on noninvasive recordings of multi-channel, EEG event-related potentials. ElMindA developed the Brain Networks Activation (BNA) platform, which provides high-resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain. The platform captures information on the composition, connectivity, synchronization, and operation of brain networks. Applications broadly for neurologic pathology. EFTA00811363 BrighTap Concept Smart water meter Stage R&D (prototype development) Contact http://www.brightao.com/ Konstantin Berezin, founder and CEO ([email protected]) Notes The BrighTap is smart water meter that attaches to any water tap, pipe, or hose. BrighTap provides water-quality and consumed-water quantity data (water quality index, liters/gallons, temperature, costs, etc.) on the product's display. BrighTap combines its in- house-developed analytic algorithm and turbine technology to measure water flow with a +/- 4% margin of error. This data can be tracked via the associated app. EarlySense Concept Contactless biometric product Stage Released Contact http://www.earlvsense.com Avner Halperin, founder and CEO ([email protected]) Notes Using data from 400,000 patients and > 100 million monitoring hours, EarlySense has developed a continuous, contact-free monitoring solution designed to enhance safety and reduce risk for general care patients. EarlySense can be used by hospitals, healthcare systems, integrated delivery networks, and rehabilitation centers. Based on piezoelectric principles and placed under a mattress or chair cushion. Super exciting ovulation-tracking product to be released next month. See supplemental reading (document) on ROI. More Purchase product on Amazon BrainQ Concept Contactless biometric product Stage Clinical trial Contact http://www.braina.co/ Yotam Dreschler, CEO ([email protected]) Notes BrainQ is a clinical-stage medical technology company that aims to significantly improve recovery from a wide variety of neurological disorders using non-invasive means. Their technology is personalized from EEG and other imaging and electrodiagnostics and delivers 0.5 gauss of focused electromagnetic stimulation to repair the neural networks at the site of injury. Data shown from patient videos and imaging demonstrates regrowth of spinal cord and brain pathology. BrainMarc Concept Wearable EEG-based cognitive training platform Stage Clinical trial Contact http://www.brainmarc.com/ Sefi Epel, co-founder and CEO ([email protected]) Notes BrainMARC has developed an EEG platform for monitoring mental activity compatible with off-the shelf devices. The company's biomarkers are applicable to a wide spectrum of neuropsychiatric syndromes where they can enhance therapeutic protocols, predict clinical dynamics, and promote general wellness. The first mobile health tools that BrainMARC developed based on its platform technology are the Brain Engagement Monitor (BEM), which measures attention-related performance biomarkers, and a EFTA00811364  Comfort Monitor (CM), which measures affect-related biomarkers. The BEM uses the Brain Engagement and Focus Events indices to provide real-time feedback regarding the effectiveness of treatment, whether pharmaceutical, electromagnetic, behavioral, or other for a variety of dysfunctions. The CM uses the Comfort and Comfort Tendency indices to provide real-time feedback regarding levels of stress, interest/memorization, and enjoyment. It can be used to assess the effectiveness of stress-reduction treatments for anxiety and migraine, as well as evaluate viewer responses to media clips. Companies Not Visited, Worth a Second Look Life Sciences Tissue Dynamics Lab on a chip Polypid Encapsulated drug delivery Sonorame Soundwave diagnostics Protekt Memory-enhancing therapeutic (Takeda/FutureRx) RetiSpec Retinal Alzheimer diagnostics Oramed Pharmaceuticals Injectable to oral therapy tech Treato Health data / social portal Aidoc Al radiology Zebra Medical Vision Al radiology Brainvivo MRI neuromarkers Valera Health Insurance-mining and compliance algorithms Myndlift Personalized neurofeedback Adaptive Technologies Sesame Enable Tablet-based tracking and communications tech Physical Sciences Sensilize Precision agriculture SolCold Solar-powered cooling (no electricity/CO2 emissions) StoreDot Amino acid-based nanodot flash batteries Supplemental Reading • Dr. Michal Schwartz short summary (larger document available...) • Return on Investment on clinical monitoring EFTA00811365